線上講座邀請：高通量藥物篩選前沿技術最新動態(tài)

瀏覽次數(shù)：2491　發(fā)布日期：2022-1-6　來源：本站　本站原創(chuàng)，轉載請注明出處

精彩前沿，不容錯過

隨著技術不斷進步，當前生命科學基礎研究和新藥研發(fā)都得到了飛速發(fā)展。特別是在新藥研發(fā)領域，不僅生物大分子藥已開始大行其道，小分子藥物也隨著PROTAC的出現(xiàn)掀起了小分子藥物研發(fā)的新浪潮。當前的新藥研發(fā)對于高通量，快速和精準的分析方案有著迫切的需求。如何在快速發(fā)展，激烈競爭的創(chuàng)新藥研發(fā)過程中，加速提質創(chuàng)新，提升藥物研發(fā)的成功率，已成為當前最引人注目的焦點。

此次網絡論壇，誠邀國際多位行業(yè)專家，共話創(chuàng)新，分享討論高通量藥物篩選前沿技術最新動態(tài)趨勢。

受邀出席專家來自
>>德國BMG LABTECH公司—專注高通量藥篩領域的多功能酶標儀廠家
>>瑞士Creoptix公司—創(chuàng)新研發(fā)出GCI超靈敏超快速分析無標記分子相互作用的廠家
>>英國Domainex公司—對難靶向酶開發(fā)極具經驗的CRO

在此，我們誠邀您報名參與，希望借此機會與您及業(yè)內專家們，一起追蹤動態(tài)趨勢，討論前沿方案，助力新藥研發(fā)。

會議時間
2022年01月12日 16:00-18:00

參會方式

長按或掃描以下二維碼填表報名

主講人簡介

Ann-Cathrin Volz works as Application Specialist for BMG LABTECH with specific focus on cell-based assays. After her graduation in Nutritional Sciences at the University of Hohenheim she completed her PhD and a Postdoc in the field of Tissue Engineering. In her position, she can draw on her experience in cell culture and related microplate-based assays to support customers in assay optimisation for existing and emerging applications.

Also part of BMG´s Application Specialist team, Martin Mangold focusses on enzyme-based assays. He graduated in biology followed by a Master of Science in the field of drug research. He went on and completed his PhD in the field of medicinal chemistry at the University of Bonn. Now he uses his knowledge of enzyme-based and drug screening microplate assays to support customers with their applications and assay optimisation.

Tatiana Tiago is the Product Manager at Creoptix with over 8 years’ experience in pharma and biotech industry. Her background in molecular biology has given her a wide understanding of binding interaction analysis including label-based and label-free technologies. Tatiana holds a degree in in Medical Molecular Biology from the University of Westminster and a PhD in Neuroscience from the University of Modena and Reggio Emilia. Recently, Tatiana’s focus is to help life-science scientist understand GCI and optimize the label-free WAVEsystem enabling them to accelerate drug discovery.

Trevor Askwith is a cell biologist and biochemist with over 10 years’ experience of small-molecule drug discovery research. He began is drug discovery career as a cell biologist at Novartis where and has more recently worked in academic drug discovery running leading the Assay Development and Screening in the Drug Discovery Group at UCL. Trevor is now the Group Leader for Assay Biology a Domainex responsible of the biophysics, biochemistry and cell biology departments.

Dr Tom Mander has nearly 30 years of small molecule drug discovery and translational research experience in both scientific and commercial roles. After graduating and working at Amersham International plc developing radioimmunoassays, he completed his DPhil studies with Professor John Morris into the roles of microglial cells at the Department of Human Anatomy, University of Oxford in 1992. Tom joined Domainex in April 2015 as Chief Operating Officer to oversee the scientific service operations and business development activities of the company. During his time in this role, he has established a broad portfolio of pharma, biotech, academic and patient foundation clients both in the UK and overseas, launched several new services and has overseen the growth of the company. In April 2020, he took over as Chief Executive Officer after the retirement of Dr Trevor Perrior

BMG LABTECH為德國多功能酶標儀制造商，多年來專注研發(fā)酶標儀技術，特別是為科研單位，藥企和CRO的高通量藥篩應用帶來強大的優(yōu)勢。BMG高端PHERAstar系統(tǒng)在藥篩領域近年更是受到諸多認可。

瑞士Creoptix，擁有基于光柵耦合干涉技術（Grating-Coupled Interferometry ，GCI）的光學生物傳感器專利，以及外置的微流體的獨特設計和Google公司研發(fā)的自動化軟件。致力于提供高質量的動力學數(shù)據(jù)，擁有業(yè)內最靈敏準確的WAVEsystem無標記分子相互作用儀，使全球生物科學研究者可以做以前不可能做的事情，看到以前看不見的數(shù)據(jù)。憑借突破性的創(chuàng)新，避開了SPR的局限性，突破無標記技術的局限。

Domainex是一家英國老牌綜合性藥物發(fā)現(xiàn)服務公司，針對難靶向的酶開發(fā)一流。

歡迎關注伯齊官方微信（微信公眾號：Bio-Gene）

回復：BMG，查看相關視頻

長按以下二維碼可識別關注公眾號